Cumulative incidences of relapse and probabilities of RFS in AML according to the GvHD prophylaxis group. Cumulative incidence curves of relapse (a, b) and probabilities of RFS (c, d) in AML are shown for each GvHD prophylaxis group. (a, c) Standard-risk disease and (b, d) high-risk disease. The 2-year cumulative incidences of relapse for the MTX+ group and MMF+ group were 18.7% and 16.9%, respectively, in a, and 55.1% and 44.9%, respectively, in b. The 4-year probabilities of RFS for the MTX+ group and MMF+ group were 49.4% and 42.7%, respectively, in c, and 13.1% and 17.3%, respectively, in d.